Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer Patients: An Open-Labeled, Single-center, Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05206656
• Other study ID #: YYS-20200305
• Status: Completed
• Phase: Phase 2
• Start date: October 9, 2020
• Est. completion date: July 20, 2022

Study information

• Verified date: November 2022
• Source: Hunan Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eribulin is the promising agent for late-line metastatic breast cancer patients. The aim of this Phase II, double-arm, open-label and prospective clinical trial is to assess the efficacy and safety of Eribullin or Eribulin combined with Anlotinib in patients with metastatic breast cancer

Description:

The aim of the double-arm, open-label, phase II clinical trial is to assess efficacy and safety of Eribulin or Eribulin combined with Anlotinib in metastatic breast cancers. The investigator hypothesize that both Eribulin and Eribulin combined with Anlotinib may be an effective alternative treatment for metastatic breast cancers. In addition, Eribulin combined with Anlotinib might be able to improve the treatment response and progression-free survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: July 20, 2022
• Est. primary completion date: April 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age = 18 years old, voluntary consent and signed written informed consent

• ECOG 0~2

• Pathologically diagnosed HER2-negative breast cancer patients with radiologically confirmed locally advanced (stage IIIB or IIIC) or metastatic (stage IV) breast cancer; HR-positive patients were permitted

• At least one measurable disease lesion before treatment

• Never receive Eribulin Mesylate treatment or anti-angiogenetic therapies before recruitment

• Anticipated survival time is longer than three months

• Brain metastases with stable disease or without clinical symptom

• Blood routine test, liver and kidney function test meet the following criteria: PLT > 100g / L, Hb > 9g / L, Neutrophil > 2.0 g/L; AST and ALT < 2.5 upper limit of normal (ULN); Cr < 1.0 ULN; TBIL < 1.5ULN

• Previously treated with anthracycline-based and taxane-based chemotherapy regimens (at least one line of chemotherapy in the metastatic setting or the recurrence time is less than 1 year from the end of adjuvant or neoadjuvant chemotherapy); for HR-positive/HER2-negative patients, progressed after at least one line of endocrine therapy

• For women with fertility, the pregnancy test before administration was negative, and agreed to take appropriate measures to avoid pregnancy during the study treatment and at least half a year after the end of treatment; Men agreed to take appropriate contraceptive measures during the study treatment and at least half a year after the end of the treatment.

Exclusion Criteria:

• Pregnant or lactating women

• Active infection requiring systemic treatment

• HIV positive

• Suffering from or suspected of suffering from central neuromuscular system diseases

• Serious heart disease; uncontrollable hypertension; history of heavy hemorrhea;recent operation within three months

• The investigator considered that the patient was not suitable for in this study, with any other situation.

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Eribulin Mesylate
Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
• Anlotinib
12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.

Locations

Country	Name	City	State
China	Hunan Cancer Hospital	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Hunan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival	The time from the date of recruitment to the date of first documented progression or date of death from any cause	through study completion, up to 6 months.
Secondary	Disease Control Rate (DCR)	The total rate of CR+PR+SD after the completion of two cycles of treatment	At the end of Cycle 2 (42 days).
Secondary	Overall survival (OS)	The survival time from the date of recruitment to the date of death from any cause	through study completion, an average of 2 year
Secondary	Objective response rate (ORR)	The total rate of CR+PR after the completion of two cycles of treatment	At the end of Cycle 2 (42 days).
Secondary	Adverse Events	All adverse events [including adverse events (AE / SAE) and ADR (adverse drug reactions)] will be collected when known. The classification of adverse reactions shall refer to CTCAE5.0 in case of adverse events / reactions. In case of serious adverse events, the investigators must immediately take necessary treatment measures to protect the safety of subjects. All adverse events / reactions should be tracked and observed. If the adverse events have not recovered, the investigator shall continue to give necessary treatment, report and record, and deal with special cases according to the management opinions of relevant departments.	through study completion, up to 6 months.
Secondary	Patient Report Outcome (PRO)	HRQoL was assessed using FACT-B at baseline and months 1,3 ,6, 9 and 12 (end of treatment). Questionnaires were administered in the local language and completed independently by patients using paper document during visits to their reference center and before any clinical procedures.	through study completion, up to 6 months.